Hepatic Manifestations of Inflammatory Bowel Disease

Patel, Parita; Dalal, Sushila

doi:10.1002/cld.1046

Cited by 6 publications

(4 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In contrast, Crohn's disease is associated with granulomatous hepatitis, liver abscess, cholelithiasis, hepatic amyloidosis, and NAFLD. 19…”

Section: Ibd Associated Liver Diseasementioning

confidence: 99%

“…PSC can also lead to complications such as cholelithiasis, cholecystitis, gallbladder cancer, cholangiocarcinoma, cholangitis, and colorectal cancer. 19,21 Unexplained cholestasis in IBD patients warrants further investigation by MRCP and on the other hand, those with PSC should undergo routine examination of colonoscopy with biopsy. Commonly the diagnosis of IBD precedes the diagnosis of PSC, although either of them could occur at different times.…”

Section: Primary Sclerosing Cholangitismentioning

confidence: 99%

See 1 more Smart Citation

Liver Disease Associated with Inflammatory Bowel Disease

Kurniawan,

Budiman

2024

InaJGHE

View full text Add to dashboard Cite

Inflammatory Bowel Disease (IBD) is a chronic condition characterized by persistent inflammation of the gastrointestinal tract, comprising ulcerative colitis (UC) and Crohn’s disease (CD). While the current global incidence of IBD exceeds 0.3% in Western nations, Indonesia reports a comparatively lower prevalence however with projections indicate a potential rise in incidence from 2020 to 2050. Hepatobiliary manifestation is one of the most common extraintestinal manifestations of IBD. Some of the liver disease associated with IBD had similar background immune response, inflammatory reaction, similar risk factor, or due to the treatment of IBD. Primary sclerosing cholangitis (PSC) has close association with IBD and both affect the prognostic and disease progression of each other. Non-alcoholic fatty liver disease (NAFLD) shares common metabolic risk factors. Several drugs used as the treatment of IBD might cause hepatic injury especially due to the long treatment duration of IBD. Hepatitis B reactivation is another concerning event found after prolonged used of immunosuppressive drugs of IBD. Therefore, close monitoring of liver function test periodically is a mandatory test to screen liver disease in IBD patients. Keyword: Inflammatory bowel disease, liver disease, autoimmune hepatitis, drug-induced liver injury

show abstract

“…In contrast, Crohn's disease is associated with granulomatous hepatitis, liver abscess, cholelithiasis, hepatic amyloidosis, and NAFLD. 19…”

Section: Ibd Associated Liver Diseasementioning

confidence: 99%

Section: Primary Sclerosing Cholangitismentioning

confidence: 99%

Liver Disease Associated with Inflammatory Bowel Disease

Kurniawan,

Budiman

2024

InaJGHE

View full text Add to dashboard Cite

show abstract

“…1 Around 5% of IBD patients may have underlying hepatobiliary disease while a third could have derangements in liver function tests. 1 2 Therefore, any strategy which is effective in preventing hepatic morbidity in these patients should be implemented. Vaccination is an effective strategy for prevention of hepatitis A virus (HAV) and hepatitis B virus (HBV) and has been recommended for IBD patients by various guideline panels.…”

Section: Introductionmentioning

confidence: 99%

“…Liver disease in patients with IBD may be related to the extraintestinal manifestations, adverse effects of various therapies, or as a consequence of underlying viral infections which may flare due to use of immunosuppression. 1 Around 5% of IBD patients may have underlying hepatobiliary disease while a third could have derangements in liver function tests. 1,2 Therefore, any strategy which is effective in preventing hepatic morbidity in these patients should be implemented.…”

Section: Introductionmentioning

confidence: 99%

Systematic Review and Meta-Analysis: Seroprevalence, Vaccination Rates, and Response for Hepatitis A in Inflammatory Bowel Disease

Jena,

Singh,

Neelam

et al. 2022

Journal of Gastrointestinal Infections

View full text Add to dashboard Cite

Introduction Guidelines recommend hepatitis A virus (HAV) vaccination in individuals with inflammatory bowel disease (IBD). We performed a systematic review to inform the clinical practice regarding this guidance. Methods After a PubMed and Embase search, duplicates were removed and the remaining titles screened for studies reporting relevant outcomes. Pooled seroprevalence rates for HAV, pooled vaccination rates, and pooled seroconversion rates were calculated. We also calculated pooled relative risk of seroprevalence for HAV among IBD and control population. Heterogeneity was investigated using subgroup analysis. Results The pooled seroprevalence of HAV antibodies in patients with IBD (14 studies, 2,370 patients) was 0.36 (95% confidence interval [CI]: 0.22–0.53, I 2 = 95%). On comparing the seroprevalence of HAV in IBD with controls (4 studies), the pooled relative risk was not different between the two (0.94, 95% CI: 0.66–1.34, I 2 = 76%). The pooled seroconversion rate after two doses of HAV vaccination (5 studies, 221 patients) was 0.93 (95% CI: 0.88–0.96, I 2 = 0%). Three studies (104 patients) reported on the seroconversion after a single dose of HAV vaccination and the pooled seroconversion rate was 0.47 (95% CI: 0.35–0.59, I 2 = 20%). The pooled vaccination rate for hepatitis A among patients with IBD (18 studies, 9,521 patients) was 0.21 (95% CI: 0.14–0.30, I 2 = 99%). Conclusion Hepatitis A vaccine has good immunogenicity in patients with IBD. The decision to routinely vaccinate IBD patients may be made in light of underlying seroprevalence of HAV.

show abstract